Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review

Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized melanoma treatment. Approximately half of patients with melanoma harbor a BRAF gene mutation with subsequent dysregulation of the RAF-MEK-ERK signaling path...

Descripción completa

Detalles Bibliográficos
Autores principales: Glen, Claire, Tan, Yun Yi, Waterston, Ashita, Evans, Thomas R. Jeffry, Jones, Robert J., Petrie, Mark C., Lang, Ninian N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040125/
https://www.ncbi.nlm.nih.gov/pubmed/35492830
http://dx.doi.org/10.1016/j.jaccao.2022.01.096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040125/
https://www.ncbi.nlm.nih.gov/pubmed/35492830
http://dx.doi.org/10.1016/j.jaccao.2022.01.096

Ejemplares similares